| scholarly article | Q13442814 |
| P50 | author | Grant Dorsey | Q60029509 |
| Moses R Kamya | Q60043817 | ||
| Philip J Rosenthal | Q60060211 | ||
| Adithya Cattamanchi | Q91293754 | ||
| P2093 | author name string | Daniel Kyabayinze | |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria | Q12156 |
| Plasmodium falciparum | Q311383 | ||
| pyrimethamine | Q421072 | ||
| P304 | page(s) | 247-252 | |
| P577 | publication date | 2003-09-01 | |
| P1433 | published in | American Journal of Tropical Medicine and Hygiene | Q15766943 |
| P1476 | title | Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria | |
| P478 | volume | 69 |
| Q30483123 | A database of antimalarial drug resistance |
| Q37190605 | A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria |
| Q34393404 | Analysis of the dihydrofolate reductase-thymidylate synthase gene sequences in Plasmodium vivax field isolates that failed chloroquine treatment |
| Q37323427 | Decreasing efficacy of antimalarial combination therapy in Uganda is explained by decreasing host immunity rather than increasing drug resistance |
| Q34014169 | Drug coverage in treatment of malaria and the consequences for resistance evolution--evidence from the use of sulphadoxine/pyrimethamine |
| Q35129708 | Drug resistance to sulphadoxine-pyrimethamine in Plasmodium falciparum malaria in Mlimba, Tanzania |
| Q35635957 | Estimating true antimalarial efficacy by heteroduplex tracking assay in patients with complex Plasmodium falciparum infections |
| Q37121532 | Extended high efficacy of the combination sulphadoxine-pyrimethamine with artesunate in children with uncomplicated falciparum malaria on the Benin coast, West Africa |
| Q28125913 | Genetic mutations in Plasmodium falciparum and Plasmodium vivax dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) in Vanuatu and Solomon Islands prior to the introduction of artemisinin combination therapy |
| Q38514109 | Genetic variations of the dihydrofolate reductase gene of Plasmodium vivax in Mandalay Division, Myanmar |
| Q36940415 | High rates of parasite recrudescence following intermittent preventive treatment with sulphadoxine-pyrimethamine during pregnancy in Benin |
| Q35755266 | Media, health workers, and policy makers' relationship and their impact on antimalarial policy adoption: a population genetics perspective |
| Q37121527 | Molecular characterization of antifolates resistance-associated genes, (dhfr and dhps) in Plasmodium vivax isolates from the Middle East |
| Q33356795 | Molecular epidemiology of drug-resistant malaria in western Kenya highlands |
| Q35171924 | Molecular monitoring of resistant dhfr and dhps allelic haplotypes in Morogoro and Mvomero districts in south eastern Tanzania. |
| Q34087282 | Mutations in the antifolate-resistance-associated genes dihydrofolate reductase and dihydropteroate synthase in Plasmodium vivax isolates from malaria-endemic countries |
| Q28473479 | Origin and evolution of sulfadoxine resistant Plasmodium falciparum |
| Q35505497 | Placental Plasmodium falciparum malaria infection: operational accuracy of HRP2 rapid diagnostic tests in a malaria endemic setting |
| Q37429678 | Placental malaria among HIV-infected and uninfected women receiving anti-folates in a high transmission area of Uganda |
| Q33817605 | Plasmodium falciparum dihydrofolate reductase and dihyropteroate synthase mutations and the use of trimethoprim-sulfamethoxazole prophylaxis among persons infected with human immunodeficiency virus |
| Q37262379 | Plasmodium falciparum mutant haplotype infection during pregnancy associated with reduced birthweight, Tanzania |
| Q33645352 | Plasmodium falciparum resistance to anti-malarial drugs in Papua New Guinea: evaluation of a community-based approach for the molecular monitoring of resistance |
| Q36391717 | Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum |
| Q37035250 | Prevalence of pfmdr1, pfcrt, pfdhfr and pfdhps mutations associated with drug resistance, in Luanda, Angola |
| Q36835042 | Prevalence of the molecular marker of Plasmodium falciparum resistance to chloroquine and sulphadoxine/pyrimethamine in Benin seven years after the change of malaria treatment policy |
| Q34748630 | Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial |
| Q36786675 | Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique |
| Q28469083 | Rifampicin/Cotrimoxazole/Isoniazid versus mefloquine or quinine + sulfadoxine- pyrimethamine for malaria: a randomized trial |
| Q21133667 | Safety and efficacy of co-trimoxazole for treatment and prevention of Plasmodium falciparum malaria: a systematic review |
| Q30541962 | Spatiotemporal mathematical modelling of mutations of the dhps gene in African Plasmodium falciparum |
| Q31064063 | Sulfadoxine resistance in Plasmodium vivax is associated with a specific amino acid in dihydropteroate synthase at the putative sulfadoxine-binding site |
| Q35541212 | The evolution of pyrimethamine resistant dhfr in Plasmodium falciparum of south-eastern Tanzania: comparing selection under SP alone vs SP+artesunate combination |
| Q36649305 | The usefulness of twenty-four molecular markers in predicting treatment outcome with combination therapy of amodiaquine plus sulphadoxine-pyrimethamine against falciparum malaria in Papua New Guinea |
| Q30483555 | World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria |
Search more.